Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Use of azathioprine and the risk of cancer in inflammatory bowel disease.

Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A.

Am J Epidemiol. 2013 Jun 1;177(11):1296-305. doi: 10.1093/aje/kws375. Epub 2013 Mar 20.

PMID:
23514635
2.

Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.

Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R.

J Gastroenterol Hepatol. 2012 Feb;27(2):385-9. doi: 10.1111/j.1440-1746.2011.06865.x.

PMID:
21793904
4.

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.

Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE.

Am J Gastroenterol. 2011 Dec;106(12):2146-53. doi: 10.1038/ajg.2011.283. Epub 2011 Oct 25.

PMID:
22031357
5.

Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.

Armstrong RG, West J, Card TR.

Am J Gastroenterol. 2010 Jul;105(7):1604-9. doi: 10.1038/ajg.2009.745. Epub 2010 Jan 26.

PMID:
20104215
6.

Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.

Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, Munkholm P, Hviid A, Jess T.

JAMA. 2014 Jun 18;311(23):2406-13. doi: 10.1001/jama.2014.5613.

PMID:
24938563
7.

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.

Fraser AG, Orchard TR, Robinson EM, Jewell DP.

Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32.

8.

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE.

Lancet. 1994 May 21;343(8908):1249-52.

PMID:
7910274
9.

Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.

Munk EM, Pedersen L, Floyd A, Nørgård B, Rasmussen HH, Sørensen HT.

Am J Gastroenterol. 2004 May;99(5):884-8.

PMID:
15128355
10.

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.

Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, Meenan J, Yim A, Sanderson J.

Aliment Pharmacol Ther. 2002 Oct;16(10):1743-50.

11.

Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.

Vos AC, Bakkal N, Minnee RC, Casparie MK, de Jong DJ, Dijkstra G, Stokkers P, van Bodegraven AA, Pierik M, van der Woude CJ, Oldenburg B, Hommes DW; Initiative on Crohn's and Colitis (ICC).

Inflamm Bowel Dis. 2011 Sep;17(9):1837-45. doi: 10.1002/ibd.21582. Epub 2010 Dec 22.

PMID:
21830262
12.

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.

Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR.

Gastroenterology. 2003 Aug;125(2):320-7.

PMID:
12891531
13.

Risk of acute pancreatitis in users of azathioprine: a population-based case-control study.

Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT.

Am J Gastroenterol. 2003 Jun;98(6):1305-8.

PMID:
12818274
14.

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD.

Gut. 2005 Aug;54(8):1121-5.

15.

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.

Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, Duclos B, Seksik P, Mary JY, Colombel JF.

Gut. 2007 Oct;56(10):1404-9. Epub 2007 May 15.

16.

Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?

Fangbin Z, Xiang G, Minhu C, Liang D, Feng X, Min H, Pinjin H.

Ther Drug Monit. 2012 Dec;34(6):695-701. doi: 10.1097/FTD.0b013e3182731925.

PMID:
23149442
17.

Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.

Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadié M, Beaugerie L, Peyrin-Biroulet L; CESAME Study Group.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1324-9. doi: 10.1016/j.cgh.2014.02.026. Epub 2014 Feb 26.

PMID:
24582568
18.

Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.

Jess T, Winther KV, Munkholm P, Langholz E, Binder V.

Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93.

PMID:
14984375
19.

The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.

Gao X, Zhang FB, Ding L, Liu H, Wang XD, Chen BL, Bi HC, Xiao YL, Zhao LZ, Chen MH, Huang M, Hu PJ.

Eur J Gastroenterol Hepatol. 2012 Aug;24(8):958-64. doi: 10.1097/MEG.0b013e3283545ae3.

PMID:
22664938
20.

Supplemental Content

Support Center